摘要
目的通过观察支气管哮喘慢性持续期患者雾化吸入普米克令舒治疗3个月骨密度的变化,评定普米克令舒对机体骨质疏松的影响。方法将支气管哮喘慢性持续期患者40例随机分成2组,治疗组给予雾化吸入普米克令舒,对照组给予安慰剂吸入,观察2组治疗前后骨密度变化。结果与对照组比较,治疗组临床症状、FEV1/FVC以及FEV1占预计值百分比明显增加,骨密度无明显变化。结论普米克令舒对支气管哮喘慢性持续期患者骨密度无明显影响。
Objective It is to observe the changes of bone density in patients with bronchial asthma in chronic persistent period after 3 month' s treatment with pulmicort nebulization, to evaluate this drug' s effect on body osteoporosis. Methods 40 cases of patients with chronic bronchial asthma were randomly divided into two groups, the treatment group was given inhala- tion pulmicort, and the control group was given placebo inhalation. Bone mineral densities were observed in both groups before and after treatment. Results Compared with control group, clinical symptoms, FEV/FVC% and FEV1 expected to account for the percentage values significantly increased in treatment group, but no significant change of bone mineral density was found. Conclusion Pulmicort has no significant effect on bone mineral density in bronchial asthma patients in chronic persistent period.
出处
《现代中西医结合杂志》
CAS
2012年第20期2184-2185,共2页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
普米克令舒
支气管哮喘慢性持续期
骨密度
Pulmicort
bronchial asthma
chronic persistent period
bone mineral density